J8611 Methotrexate (jylamvo) - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Methotrexate (jylamvo)

Brand Name:

Jylamvo

Strength:

2.5mg

HCPCS:

J8611

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Antimetabolite

Minor Drug Class:

Folic Acid Analog

Oral (Y/N):

Yes

FDA Approval Year:

2023

FDA Discontinuation Year:

CMS Effective Date:

June 10, 2024

CMS Discontinuation Date:

Status:

In Use